Articles by Marie Carlo, MD
Conclusions: Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
ByBrian I. Rini, MD,Mehmet Asim Bilen, MD,Marie Carlo, MD,Robert J. Motzer, MD,Moshe Ornstein, MD, MA,Rana R. McKay, MD,Tom Powles, MBBS, MRCP, MD Brian Rini, MD, summarizes the thoughts of his colleagues on the use of lenvatinib plus pembrolizumab to treat advanced renal cell carcinoma.
The Exciting Future of Advanced Renal Cell Carcinoma Management
ByMarie Carlo, MD,Mehmet Asim Bilen, MD,Robert J. Motzer, MD,Moshe Ornstein, MD, MA,Brian I. Rini, MD,Rana R. McKay, MD,Tom Powles, MBBS, MRCP, MD A panel of oncologists look at what’s in the pipeline for advanced renal cell carcinoma, including trials and treatment options.
Unmet Needs in Advanced Renal Cell Carcinoma Management
ByMehmet Asim Bilen, MD,Marie Carlo, MD,Robert J. Motzer, MD,Moshe Ornstein, MD, MA,Brian I. Rini, MD,Rana R. McKay, MD,Tom Powles, MBBS, MRCP, MD Two kidney cancer experts explore the current unmet needs for patients with advanced renal cell carcinoma.
Unmet Needs in the Front-Line Setting for Renal Cell Carcinoma
ByMehmet Asim Bilen, MD,Marie Carlo, MD,Robert J. Motzer, MD,Moshe Ornstein, MD, MA,Brian I. Rini, MD,Rana R. McKay, MD,Tom Powles, MBBS, MRCP, MD A look at the current unmet needs in front-line renal cell carcinoma treatment.
Patient Quality of Life on Lenvatinib plus Pembrolizumab Treatment for Renal Cell Carcinoma
ByMehmet Asim Bilen, MD,Marie Carlo, MD,Robert J. Motzer, MD,Moshe Ornstein, MD, MA,Brian I. Rini, MD,Rana R. McKay, MD,Tom Powles, MBBS, MRCP, MD Oncologists review quality of life data for patients with renal cell carcinoma receiving lenvatinib plus pembrolizumab combination treatments.
Dosing Lenvatinib for Treatment of Advanced Renal Cell Carcinoma
ByMehmet Asim Bilen, MD,Marie Carlo, MD,Robert J. Motzer, MD,Moshe Ornstein, MD, MA,Brian I. Rini, MD,Rana R. McKay, MD,Thomas Powles, MBBS, MCRP, MD Kidney cancer experts explain how they dose lenvatinib in advanced renal cell carcinoma treatment to mitigate toxicities.
Dosing Lenvatinib for First-Line Renal Cell Carcinoma Treatment
ByMehmet Asim Bilen, MD,Marie Carlo, MD,Robert J. Motzer, MD,Moshe Ornstein, MD, MA,Brian I. Rini, MD,Rana R. McKay, MD,Thomas Powles, MBBS, MD, MRCP An explanation of dosing strategies when treating patients with renal cell carcinoma in the first-line with lenvatinib.
Treating Favorable Risk Patients with Renal Cell Carcinoma with Lenvatinib
ByMehmet Asim Bilen, MD,Marie Carlo, MD,Robert J. Motzer, MD,Moshe Ornstein, MD, MA,Brian I. Rini, MD,Rana R. McKay, MD,Tom Powles, MBBS, MRCP, MD Experts discuss the safety of treating renal cell carcinoma with lenvatinib within different patient risk populations.
Risk Factors in the Management of Advanced Renal Cell Carcinoma
ByMehmet Asim Bilen, MD,Marie Carlo, MD,Robert J. Motzer, MD,Moshe Ornstein, MD, MA,Brian I. Rini, MD,Rana R. McKay, MD,Tom Powles, MBBS, MRCP, MD Possible comorbidities and other risk factors in advanced renal cell carcinoma that would affect potential treatment regimens.
Choosing a Combination Treatment for Advanced Renal Cell Carcinoma
ByMehmet Asim Bilen, MD,Marie Carlo, MD,Robert J. Motzer, MD,Moshe Ornstein, MD, MA,Brian I. Rini, MD,Rana R. McKay, MD,Tom Powles, MBBS, MRCP, MD A look at the factors considered in choosing an appropriate combination treatment for advanced renal cell carcinoma.
Choosing a First-Line Combination Treatment Regimen for Renal Cell Carcinoma
ByMehmet Asim Bilen, MD,Marie Carlo, MD,Robert J. Motzer, MD,Moshe Ornstein, MD, MA,Brian I. Rini, MD,Rana R. McKay, MD,Tom Powles, MBBS, MRCP, MD Drs Rana McKay and Tom Powles debate the merits of different first-line combination treatment regimens for renal cell carcinoma.
Impressions of Data and Results from the CLEAR Trial
ByMehmet Asim Bilen, MD,Marie Carlo, MD,Robert J. Motzer, MD,Moshe Ornstein, MD, MA,Brian I. Rini, MD,Rana R. McKay, MD,Tom Powles, MBBS, MRCP, MD Oncologists give their initial impressions about the results of a clinical trial studying doublet combination therapies for advanced renal cell carcinoma.
Background: Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
ByMehmet Asim Bilen, MD,Marie Carlo, MD,Robert J. Motzer, MD,Moshe Ornstein, MD, MA,Brian I. Rini, MD,Rana R. McKay, MD,Tom Powles, MBBS, MRCP, MD Robert J. Motzer, MD, presents data examined in the article, “Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.”
